#TB need to be targeted by vaccination
In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global emergency. Approx. 1.7 billion people are infected and 10.4 million people are estimated to fell ill with TB in 2016. In the same year approx. 1.4 million died because of TB; among them 253,000 children (aged 0-14 years). South Africa and other Sub-Saharan countries belong to the group of “high-burden” TB countries with an estimated 97,000 deaths each year in South Africa alone.
In children BCG can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis.
VPM1002 is an innovative live vaccine against TB, based on the well-known Mycobacterium bovis (M. bovis) Bacille Calmette-Guérin (BCG) strain which has been administered approximately 4 billion times worldwide.
The genetically modifications of VPM1002, namely introduction of listeriolysin while simultaneously deleting the gene for urease C in the BCG genome, are aiming for better recognition by the host immune system.
News and Press
The PREV-PKDL consortium prepares to start clinical trials of a candidate vaccine to prevent chronic dermal leishmaniasis in patients treated for visceral leishmaniasis. The kick-off meeting will take place in York (UK) on 6-7 June 2018. The promising vaccine ...
EDCTP published its 2018 calls for proposals after approval of its 2018 work plan. The eleven calls represent an overall investment of €118 million in clinical research and research capacity in sub-Saharan Africa. With these calls the EDCTP grant portfolio ...